BioXcel Therapeutics
BTAI
BTAI
94 hedge funds and large institutions have $167M invested in BioXcel Therapeutics in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 32 increasing their positions, 28 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
2% less funds holding
Funds holding: 96 → 94 (-2)
39% less capital invested
Capital invested by funds: $274M → $167M (-$106M)
Holders
94
Holding in Top 10
–
Calls
$2.11M
Puts
$1.68M
Top Buyers
| 1 | +$2.23M | |
| 2 | +$1.88M | |
| 3 | +$1.63M | |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$1.35M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$1.17M |
Top Sellers
| 1 | -$13.7M | |
| 2 | -$1.94M | |
| 3 | -$1.69M | |
| 4 |
Jane Street
New York
|
-$1.63M |
| 5 |
GCM
Graham Capital Management
Rowayton,
Connecticut
|
-$897K |